Immunitas Therapeutics utilizes single-cell genomics to develop targeted antibody-based therapies for cancer and autoimmune diseases, focusing on the CD161-CLEC2D pathway. Their lead candidate, IMT-009, is currently in clinical trials for treating refractory tumors, addressing the need for effective treatments in patients with limited options.
Funding
$97M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers and autoimmune diseases lack effective treatments, particularly for patients with refractory tumors or those who do not respond to existing therapies. There is a need for novel therapeutic approaches that can target previously unexploited pathways to improve patient outcomes.
Solution
Immunitas Therapeutics is developing differentiated antibody-based therapeutics for cancer and autoimmune diseases by leveraging single-cell genomics to identify novel targets. Their lead candidate, IMT-009, is a monoclonal antibody (mAb) targeting CD161 and is currently in Phase 1/2a clinical trials for patients with refractory tumors across various indications, including MSS Colorectal Cancer, Head and Neck Cancer, and Non-Small Cell Lung Cancer. Immunitas is also advancing a second program targeting the CD161-CLEC2D pathway for the treatment of autoimmune diseases, building on their foundational knowledge of this pathway. The company's approach aims to reinvigorate T and NK cell function and anti-tumor efficacy by blocking the interaction of CD161 with its ligand CLEC2D.
Target Audience
The primary target audience includes patients with cancer and autoimmune diseases, particularly those with refractory tumors or limited treatment options, as well as clinicians and researchers in the fields of immuno-oncology and autoimmune disease.
Features
- IMT-009: A fully human anti-CD161 monoclonal antibody in Phase 1/2a clinical trials.
- Targets the CD161-CLEC2D pathway to enhance T and NK cell activity.
- Development of novel anti-CLEC2D-TLR9 agonist conjugates.
- Utilizes single-cell genomics for target discovery and validation.
- Focus on developing therapies for both solid tumors and hematological malignancies.
- Preclinical data supports combination of IMT-009 with anti-PD1 immunotherapy.